Overview

Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.
Phase:
Phase 4
Details
Lead Sponsor:
University of Florida
Collaborator:
Novartis Pharmaceuticals
Treatments:
Cyclosporine
Cyclosporins
Tacrolimus